Effective management of bone metastases in men with castration-resistant prostate cancer (CRPC) remains an important unmet medical need. MET and vascular endothelial growth factor receptor (VEGFR) are rational targets for intervention in CRPC. Clinical trials involving agents that inhibit one but not both pathways have reported modest activity and no improvement in overall survival. Cabozantinib is an oral multitargeted tyrosine kinase inhibitor that inhibits both MET and VEGFR-2. A phase II randomized discontinuation study involving subjects with CRPC demonstrated that cabozantinib therapy is associated with improvement in bone scans, bone turnover markers, and pain response, but with significant adverse events leading to dose reduction and treatment discontinuation. Lower doses of cabozantinib retain high levels of activity with less toxicity. Ongoing phase III clinical trials will define the role of cabozantinib in CRPC. We summarize the rationale for targeting MET and VEGFR pathways in CRPC and the clinical data available to date.
Pathophysiology of Bone Metastasis in Prostate Cancer
Bone metastasis in prostate cancer involves complex heterotypic interactions between prostate cancer cells, osteoblasts, osteoclasts, bone matrix, and endothelial cells. The bone microenvironment contains high concentrations of growth factors in the marrow and immobilized in the matrix. 2 Increased bone turnover due to bone metastasis is reflected in elevated bonespecific alkaline phosphatase and urinary N-telopeptide (NTx), markers of osteoblast and osteoclast activities, respectively.
Prostate cancer bone metastases are characterized by radiographically dense ''osteoblastic'' lesions on plain films. Despite this appearance, bone metastases due to prostate cancer are associated with high osteoclast activity and consequently have compromised structural integrity. 3 The balance of bone turnover activity is mediated by receptor activator of nuclear factor JB (RANK) and RANK ligand (RANKL). RANK is present on osteoclasts, and RANKL is expressed by osteoblasts and bone marrow stromal cells. RANKL binding to RANK leads to differentiation of osteoclast precursors as well as to activation and survival of mature osteoclasts. 2 
MET and Vascular Endothelial Growth Factor Receptor Pathways and Bone Turnover
In addition to RANK/RANKL activity, the MET receptor tyrosine kinase and the vascular endothelial growth factor (VEGF) signaling pathways play important roles in normal and pathological bone metabolism. Osteoblasts and osteoclasts express MET, and MET signaling is important for growth and activity of these cells. 4 Hepatocyte growth factor (HGF), the ligand for MET, can substitute for macrophage colony-stimulating factor and promote proliferation, survival, and osteoclastogenesis from CD14+ monocytes. 5 Hepatocyte growth factor induces osteoblasts to enter the cell cycle and to express bone morphogenetic protein 2, a protein required for bone formation and repair. 4, 6 Both osteoblasts and osteoclasts have been shown to secrete HGF. 4, 7 Together, these findings suggest that HGF/MET signaling plays important dual roles in autocrine and paracrine regulation of growth, survival, and activity of osteoclasts and osteoblasts.
Vascular endothelial growth factor signaling is similarly important for osteoblast and osteoclast activity and survival. Osteoblasts and osteoclasts also express VEGF receptors (VEGFRs). Murine osteoblasts have been shown to express VEGFR-1 and VEGFR-2 during differentiation, as well as the ligand VEGF-A, which is maximally expressed during mineralization. 8 Human osteoblasts similarly express functional VEGFRs and VEGF. 9 Vascular endothelial growth factor treatment inhibits apoptosis of human osteoblasts via increased expression of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) in vitro, whereas neutralizing antibodies to VEGF induced apoptosis. 9 Human osteoclasts express VEGFR-1, -2, and -3 throughout fetal and adult life. 10 Human osteoclasts express VEGF-A in vitro in a RANKL/nuclear factor JB/hypoxia-inducible factor (HIF)-1>dependent manner, especially in large osteoclasts. 11 Thus, similar to HGF/MET signaling, VEGF/VEGFR signaling mediates both autocrine and paracrine roles in activity and survival of osteoblasts and osteoclasts. Although the precise interactions between vascular cells and bone-forming cells are unclear, VEGFR signaling may mediate the close association between angiogenesis and bone formation in fracture healing and may play similar roles in pathogenesis of bone metastasis.
MET and VEGFR Pathways and Prostate Cancer
MET and VEGFR signaling pathways play important roles in both prostate cancer progression and bone metastasis. MET is expressed in basal and atrophic luminal cells of normal prostate epithelium 12 and is present at low levels in prostate cancer cells. 12 MET expression is repressed by the androgen receptor in a ligand-dependent manner in vitro. 13 Androgen deprivation increases MET expression in prostate cancer cells and also increases tumor and stromal expression of HGF. 13, 14 Increased expressions of MET and/or HGF correlate with prostate cancer metastasis and disease recurrence. 14, 15 In a comparison of bone, lymph node, and soft tissue metastases from patients with prostate cancer, MET expression was highest in bone metastases. 15 Thus, increased expression of MET and/or HGF may contribute to prostate cancer metastasis to bone. Androgen deprivation therapy, the standard initial therapy for metastatic prostate cancer, may enhance MET signaling by increased expression of both MET and its ligand HGF.
Vascular endothelial growth factor receptor signaling is critical for angiogenesis, a key step in tumor growth. Compared with normal prostate and high-grade prostatic intraepithelial neoplasia, prostate cancers have significantly higher microvessel density that correlates with higher tumor grade and pathological stage. 16 Prostate cancers express VEGFR-2, with higher levels in high-grade disease. 16 Prostate cancer cells, but not benign prostatic epithelial cells, express VEGF. 17 Patients with metastatic prostate cancer have higher plasma VEGF levels. 18 Levels of plasma or urine VEGF are independent predictors of overall survival (OS) in men with metastatic CRPC. 19, 20 Vascular endothelial growth factor and MET interact in prostate cancer cells. Myeloid cell leukemia 1 (Mcl-1), a member of the Bcl-2 family of antiapoptotic proteins, is significantly expressed in high-grade prostate cancer and bone metastasis. 21 Vascular endothelial growth factor induces Mcl-1 expression in prostate cancer cells in a MET-dependent manner via the coreceptor neuropilin 1. 21 The activities of MET and VEGFR signaling in bone turnover and prostate cancer metastasis to bone provide a strong rationale for dual inhibition of VEGF and MET as a therapeutic strategy in men with CRPC and bone metastases.
Quantitative Evaluation of Bone Lesions
Endpoints in clinical trials of agents affecting bone metastases are an important consideration in prostate cancer and other malignancies with high prevalence of bone metastasis. Bone lesions change slowly over time and are considered nonmeasurable sites of disease by modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. 22 99m Tcmethylene diphosphonate (MDP) bone scans measure the hydroxyapatite-rich inorganic matrix derived from osteoblastic activity and do not directly measure tumor activity. Posttreatment bone scan changes reflect altered 99m Tc-MDP binding by the inorganic matrix due to changes in perfusion in the region of the tumor, direct down-regulation of osteoblast function with attendant decreased matrix formation, enhanced matrix destruction, or a combination of such factors. There has been no standard criteria for bone scan imaging results or posttreatment changes, which can lead to subjective interpretation. Endpoints involving bone scan changes typically involve increase in bone scan lesion number but lack quantifiable metrics to evaluate for posttreatment response. 22 Recently, a computer-aided detection (CAD) assessment system was developed to provide objective, reproducible, and quantifiable measurements of 99m Tc-MDP uptake in bone. 23 The CADrx system integrates image intensity normalization, anatomic region-specific intensity thresholding, and quantitation of disease burden, along with independent nuclear medicine physician review. Bone scan lesion area (BSLA), bone scan lesion intensity, and bone scan lesion count were tested as metrics to assess posttreatment effects in prostate cancer subjects receiving cabozantinib, a MET/VEGFR inhibitor (see below). The most significant metric to differentiate between untreated and treated subjects was BSLA. 23 Validation of BSLA as an objective measurement of posttreatment response compared with clinically relevant outcome measures is underway.
VEGFR-and MET-Targeted Therapies in CRPC: Clinical Evidence
Several agents targeting either VEGFR activity, MET activity, or both have been evaluated in men with CRPC. Notable contemporary trials are summarized in Table 1 .
VEGF/VEGFR Inhibition in Clinical Trials in CRPC
Five agents targeting angiogenesis have reached phase III clinical trials in CRPC. To date, inhibition of VEGF/VEGFR signaling has not improved OS in men with CRPC.
Bevacizumab
Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF activity. A phase II study (CALGB 90006) of bevacizumab combined with docetaxel and estramustine suggested an improvement in OS. 24 CALGB 90401 enrolled 1050 subjects with progressive, metastatic CRPC. 25 The primary endpoint was OS. Subjects were randomized to receive docetaxel (75 mg/m 2 every 21 days) with prednisone (5 mg b.i.d.) and either bevacizumab (15 mg/kg i.v. every 21 days) or placebo. There was no statistically significant difference in OS (22.6 vs. 21.5 months, respectively; hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.78Y1.05; P = 0.181). Median progression-free survival (PFS) and objective response were higher in the bevacizumab group, as were grade 3 or greater treatment-related toxicity and treatment-related deaths. 25 
Sunitinib
Sunitinib, an oral tyrosine kinase inhibitor (TKI) of VEGFR and PDGFR, demonstrated activity in 2 phase II studies of subjects with progressive metastatic CRPC who had received docetaxel chemotherapy. 26, 27 A phase III trial randomized 873 subjects with progressive metastatic CRPC after docetaxel chemotherapy to sunitinib (37.5 mg daily) or placebo, in a 2:1 ratio. The primary endpoint was OS. Results from a second interim analysis demonstrated no improvement in OS (13.1 vs. 12.8 months, respectively; HR, 1.03; 95% CI, 0.80Y1.32; P = 0.5813), and the data monitoring committee recommended that the trial be discontinued. These results were presented at the 2011 Annual Meeting of the American Society for Clinical Oncology (ASCO). 28 Unplanned post hoc analyses of bone scans from a phase II study of sunitinib 27 evaluated baseline and 12-week scans in 25 subjects. 29 Two radiologists specialized in nuclear medicine and 1 nuclear medicine physician assessed all images and identified ''partial responses'' (PRs) as subjective 50% overall improvement or greater in total abnormal tracer uptake (intensity Â volume) of previous metastatic bone lesions, or patients with extensively diffuse skeletal metastasis (superscan) that changed to recognizable individual metastatic lesions. Overall, 6 of 25 subjects (24%) demonstrated a response by bone scan using these criteria. One of the 6 subjects had complete response (CR, defined as no lesions indicating metastatic disease). None of the 6 demonstrated a response by prostate-specific antigen (PSA) or RECIST criteria. 29 These data, in light of significant bone scan improvement in CRPC subjects taking cabozantinib (below), highlight the potential discordance between 99m Tc-MDP bone scans and other assessments of posttreatment changes using TKIs or other targeted therapies.
Lenalidomide
Lenalidomide is an oral immunomodulatory agent with potential antineoplastic activity that also inhibits VEGF signaling and angiogenesis. 30 The MAINSAIL study randomized 1059 subjects with CRPC to docetaxel (75 mg/m 2 , once every 3 weeks) with prednisone (5 mg twice daily) and either lenalidomide (25 mg daily, days 1Y14) or placebo. The primary endpoint was OS; secondary endpoints included PFS and overall response rate. In November 2011, the data monitoring committee recommended that the study be stopped, as it was unlikely to meet its primary endpoint, and there were safety concerns. This study was described at the European Society for Medical Oncology 2012 Congress. 31 The median OS of the lenalidomide group was 77 weeks; the median was not reached in the placebo arm. Treatment with lenalidomide was associated with more neutropenia, febrile neutropenia, and diarrhea.
Aflibercept
Aflibercept, also known as VEGF-Trap, is a protein composed of the extracellular domains of VEGFR-1 and -2 fused with the constant region (Fc) of the human immunoglobulin G1 antibody. Aflibercept acts as a decoy receptor, preventing VEGF from binding to VEGFRs. The VENICE study randomized 1224 subjects with CRPC to docetaxel (75 mg/m 2 , once every 3 weeks) with prednisone (10 mg daily) and either aflibercept (6 mg/kg i.v., once every 3 weeks) or placebo. The primary endpoint was OS; secondary endpoints included PSA response, pain response, skeletal-related events, and PFS. In April 2012, the study sponsors, Sanofi and Regeneron, reported in a press release that no difference in OS was observed between the treatment arms. This study has not been presented or published for further details.
Tasquinimod
Among other therapies targeting angiogenesis in CRPC, tasquinimod has advanced to phase III testing. Tasquinimod is an oral agent with antiangiogenic and potential antineoplastic activities and has been shown to decrease blood vessel density, although the precise mechanism of action is unknown. 32 In a randomized, double-blind phase II study, 201 subjects with metastatic CRPC were assigned to either tasquinimod (1 mg daily) or placebo after a titration phase (0.25 mg daily for 2 weeks followed by 0.5 mg daily for 2 weeks). 32 After a maximum of 6 months of double-blind treatment, asymptomatic subjects on the placebo arm were offered open-label tasquinimod. Subjects on the tasquinimod arm without disease progression at 6 months could continue open-label treatment, and subjects with progression were withdrawn from study. The primary endpoint was disease progression by RECIST, Prostate Cancer Working Group, 33 or pain criteria. Six-month progression-free proportion favored the tasquinimod arm over placebo (69% vs. 37%, P G 0.001). Median PFS was longer in the tasquinimod arm over placebo (7.6 vs. 3.3 months, P = 0.0042). There was no significant difference in posttreatment PSA change between the 2 groups. Grades 3 to 4 adverse events (AEs) were more common in the tasquinimod arm (40% vs. 10%). 32 In the phase III study, a total of 1200 subjects with chemotherapy-naive CRPC will be randomized 2:1 to tasquinimod or placebo. The primary endpoint is PFS. The study is powered to detect an improvement in OS as a secondary endpoint. This study is ongoing and currently accruing patients.
MET Inhibition in Clinical Trials in CRPC
MET-targeted therapies in development include monoclonal antibodies and small-molecule TKIs. Two therapies that inhibit MET signaling have reached phase II clinical trials specifically enrolling CRPC patients.
Rilotumumab
Rilotumumab (AMG102) is a fully human monoclonal antibody to HGF. A phase II study randomized 142 men with progressive CRPC after taxane chemotherapy 1:1:1 to mitoxantrone (12 mg/m 2 every 3 weeks) with prednisone (5 mg twice daily) and either rilotumumab (15 mg/kg i.v. every 3 weeks), rilotumumab (7.5 mg/kg i.v. every 3 weeks), or placebo. The primary endpoint was OS. Rilotumumab did not improve OS (13.4 vs. 11.6 vs. 11.1 months, respectively). Rilotumumab was not associated with any significant differences in PFS or PSA response. These data were presented at the 2012 ASCO Genitourinary Cancers Symposium. 34 Tivantinib Tivantinib (ARQ 197) is an oral TKI that binds to MET protein, disrupting MET signal transduction pathways. A randomized phase II study is currently enrolling subjects with chemotherapy-naive, minimally symptomatic, or asymptomatic metastatic CRPC. Subjects will receive tivantinib orally twice daily or placebo. The primary endpoint is PFS.
Other therapies targeting MET signaling are in earlier phases of clinical development with respect to CRPC. Monoclonal antibodies include onartuzumab (MetMab), TAK-701, and ficlatuzumab (SCH900105). Small-molecule TKIs include SGX523, PF-04217903, EMD 1214063, EMD 1204831, PF-02341066 (crizotinib [Xalkori]), BMS-777607, SAR125844, and JNJ-38877605.
Dual Inhibition of MET and VEGFR Signaling in CRPC: Clinical Evidence
Tyrosine kinase inhibitors that target both MET and VEGFR signaling are in development. Cabozantinib has advanced to phase III trials in CRPC and is the subject of the remainder of this review. Other therapies that target both MET and VEGFR signaling are in earlier phases of clinical development with respect to CRPC, including foretinib (GSK1363089), golvatinib (E7050), GSK1363089 (XL880), and MGCD265.
Cabozantinib
Cabozantinib (XL184) is an oral small-molecule TKI. The primary targets of cabozantinib are VEGFR-2, MET, a mutationally activated form of RET, and KIT. 35 Dual inhibition of VEGFR and MET signaling by cabozantinib has shown promise in metastatic CRPC 36 and other malignancies. In medullary thyroid cancer, activating RET mutations are commonly associated with both inherited and sporadic forms of the disease. The phase I trial of cabozantinib (140 mg daily freebase weight) yielded early evidence of clinical benefit in medullary thyroid cancer, with 68% of subjects exhibiting stable disease (SD) or confirmed PR. 37 The EXAM study is the only completed phase III study of cabozantinib to date. The EXAM study randomized 330 subjects with progressive, locally advanced, or metastatic medullary thyroid cancer to cabozantinib or placebo. The primary endpoint was PFS. Cabozantinib improved PFS (11.2 vs. 4.0 months; HR, 0.28; 95% CI, 0.19Y0.40; P G 0.0001). An interim analysis of OS (a secondary endpoint) at 44% of 217 required events did not show a difference between cabozantinib or placebo. 38 Cabozantinib is now Food and Drug Administration approved for treatment of advanced medullary thyroid cancer. Other malignancies that have demonstrated responsiveness to cabozantinib in phase II clinical trials include renal, 39 ovarian, 40 liver, 41 melanoma, 42 breast, 43 and nonYsmall cell lung cancer. 44 
Phase II Randomized Discontinuation Study
Phase I trial evidence of tumor regression in response to cabozantinib in multiple tumor types led to a phase II randomized discontinuation study in 9 selected tumor types (study XL184-203), including metastatic CRPC. In the CRPC group, enrolled subjects had progressive metastatic CRPC with measurable disease by mRECIST criteria, continued castration therapy, and no more than 1 prior standard chemotherapy regimen. Cabozantinib (100 mg freebase weight) was administered daily during a 12-week lead-in stage. Subsequent treatment was based on response at 12 weeks: subjects with response by mRECIST criteria continued open-label cabozantinib, subjects with progressive disease (PD) discontinued therapy, and subjects with SD were randomized to either placebo or continued cabozantinib. The primary endpoint for the lead-in stage was response rate per mRECIST criteria. The primary endpoint for the randomized stage was PFS. Bone disease was present at baseline in 87% of patients, and 43% were pretreated with docetaxel. 45 Randomization in the CRPC cohort was suspended after the first 122 CRPC subjects were enrolled because of unexpected high rates of bone scan improvement during the lead-in stage. An additional 49 subjects were enrolled in a nonrandomized extension, for a total of 177 CRPC subjects. Bone scans were assessed visually by an independent single reader comparing baseline scan with week 6 or week 12 scans. The response rate by mRECIST criteria was 4%, although most subjects had minor improvements in measurable disease. Unexpectedly, 75% of subjects had rapid improvement of 99m Tc-MDP bone scans, a post hoc study outcome, including 19% with complete resolution. 45 Improvements in bone scans correlated with clinical benefit, as 67% of subjects with pain at baseline reported a decrease in pain. Prostate-specific antigen changes and bone scan improvements were discordant in 40% of subjects. Dose reductions occurred in 51% of subjects by week 12, with 16% discontinuing treatment because of AEs before week 12. The most common grade 3 toxicities during the lead-in stage were fatigue (16%), hypertension (6%), and hand-foot syndrome (6%). Serious AEs included venous thromboembolic events (13 events), gastrointestinal perforation (2 events), and 1 unexplained death on study at week 33. The high rates of bone scan improvements coupled with clinical benefit supported further development of cabozantinib in men with CRPC and bone metastases.
Dose-Ranging Study
Because of the high rate of dose reduction and treatment discontinuation at 100 mg daily, a dose-ranging study was conducted to determine the efficacy and tolerability of cabozantinib at lower starting doses (NCT01347788). 46, 47 Eligible patients had progressive CRPC with bone metastases, continued castration therapy, and up to 2 prior chemotherapy regimens. The primary outcome was bone scan response at 6 weeks, measured as the posttreatment change in BSLA assessed using the CADrx system. 23 A decrease in BSLA of 30% or greater was defined as a response. Bone scans were categorized as CR, PR, SD, or unequivocal PD based on comparison of week 6 and baseline imaging. Secondary outcome measures included markers of bone turnover and effects on circulating tumor cells (CTCs) (Fig. 1) .
The study completed enrollment of 36 subjects. Median age was 66 years. Sixteen subjects (44%) had previously received docetaxel chemotherapy. An adaptive response design was used to determine the lowest active daily cabozantinib dose among dose level +1 (60 mg), dose level 0 (40 mg), and dose level j1 (20 mg), per the 1-stage design of Sargent et al. 48 Of the tested doses, a higher bone scan response rate at 6 weeks was observed with cabozantinib 40 mg daily (67%) compared with 20 mg daily (10%). Of 25 subjects who started treatment at 40 mg daily (cohort 1 and expansion cohort), 16 (64%) exhibited at least PR by week 6. The best response at 45 Subjects receiving the 40-mg starting dose were on study for median of 27 weeks (range, 2Y57 weeks). No subjects required dose reduction or delay at 6 or 12 weeks, compared with 51% in the randomized discontinuation study. 45 Discontinuations due to drug-related AEs occurred in 12% of subjects at the 40-mg starting dose before 12 weeks, compared with the 16% rate seen in the randomized discontinuation trial. 45 Reasons for discontinuing therapy by 12 weeks included fatigue and anorexia (1 subject) and venous thromboembolic event (2 subjects).
Circulating tumor cell evaluation (CellSearch Assay; Veridex LLC, Raritan, NJ) revealed that 12 subjects had ''unfavorable'' CTC levels of 5 CTCs or greater per 7.5 mL of peripheral blood at baseline. Eleven (92%) of the 12 subjects had a decrease in CTCs of greater than 30% by 12 weeks, including 7 subjects who converted to the favorable level of less than 5 CTCs. These data are consistent with either a direct anti-tumor effect by cabozantinib and/or an alteration of the bone microenvironment by cabozantinib that affects cancer viability and/or release of CTCs into the circulation.
The high rate of bone scan response and improved tolerability of the 40-mg daily starting dose have informed the design of other ongoing trials of cabozantinib in CRPC. The nonrandomized expansion cohort of trial XL184-203 was amended to include a 40-mg daily dose of cabozantinib in CRPC subjects, in addition to the 100-mg daily dose of the original protocol. The phase III trials of cabozantinib both use lower starting doses than the original phase II study.
Phase III Trials
Two phase III, randomized, double-blind, controlled trials of cabozantinib (COMET-1 and COMET-2) at 60-mg daily starting dose are currently enrolling patients with metastatic CRPC and disease progression despite prior treatment with docetaxel and either abiraterone or enzalutamide. COMET-1 compares cabozantinib with prednisone, with the primary outcome measure of OS. COMET-2 compares cabozantinib with mitoxantrone and prednisone in subjects with symptomatic disease, with the primary outcome measure of confirmed, durable pain response from week 6 to week 12.
SUMMARY
Management of bone metastasis in CRPC remains an important unmet need. Vascular endothelial growth factor receptor and MET signaling pathways are thought to play important roles in prostate cancer progression and bone metastasis and are thus rational targets for intervention in CRPC. Studies that evaluated agents that inhibit one but not both pathways have not yielded improvements in OS.
Cabozantinib, an inhibitor of both MET and VEGFR-2, is associated with improvement in bone scans, pain response, bone turnover markers, and CTCs but not PSA in men with CRPC and bone metastases. The phase II trial dose of 100 mg daily was associated with frequent AEs that led to dose reductions in most patients. 45 Lower doses of cabozantinib retain high levels of activity with less toxicity (Lee et al., submitted for publication). Ongoing phase III clinical trials will define the role of cabozantinib in CRPC.
The precise mechanism(s) of bone scan improvements with cabozantinib is undefined. Bone scans reflect altered osteoblast activity. Posttreatment bone scan changes may be caused by altered perfusion in the region of the tumor, death of tumor cells with resultant decrease in inorganic matrix, direct downregulation of osteoblast activity, or a combination of factors. Because cabozantinib and sunitinib share VEGFR as a common target, and both TKIs demonstrated bone scan improvements in CRPC, 29, 45 VEGFR inhibition may cause diminished perfusion, decreased osteoblast activity, and resultant improvement on bone scans. Cabozantinib may improve upon sunitinib's effect by inhibition of another of its targets, MET. Animal models investigating sunitinib resistance mechanisms have demonstrated increased HGF production and induction of alternative angiogenic pathways via MET-expressing endothelial cells. 49 Combined inhibition of sunitinib with the MET inhibitor PF-04217903 effectively decreased tumor growth of sunitinibresistant cancer cell lines in experimental animals. 49 Other studies examining a pancreatic neuroendocrine tumor model demonstrated similar inhibition of tumor growth, invasion, and metastasis using either cabozantinib or a combination of sunitinib and PF-04217903 in experimental animals. 50 The discordance between high rates of bone scan improvement and only mild effects of cabozantinib on soft-tissue metastases 45 may reflect differential target inhibition depending on the tumor microenvironment. The coordinated MET and VEGFR inhibition may be more effective in disrupting the bone microenvironment compared with visceral metastases because of the importance of these pathways in the interactions among prostate cancer cells, osteoblasts, osteoclasts, and vascular cells. Alteration of the bone microenvironment by cabozantinib may thus affect cancer viability or vascular integrity, reflected in the decrease in CTCs. The decrease in CTCs could also reflect a direct anti-tumor effect of cabozantinib via inhibition of cell proliferation, invasion, and metastasis, similar to preclinical models. 50 Alternatively, cabozantinib may be tumoristatic in both bone and viscera via inhibition of both VEGFR-and METmediated angiogenesis. 49 The reduced perfusion of bone tumor deposits may cause bone scan improvement, clinical benefit, and overall static tumor burden, especially in patients with bone-dominant metastatic CRPC. Assuming that serum PSA reflects overall tumor burden, the discordance of bone scan improvements, clinical benefit, and PSA change may be consistent with this model. We have observed moderate fluctuation of PSA during prolonged (912 weeks) cabozantinib treatment, which could reflect a waxing and waning tumor burden that cannot escape effective angiogenesis inhibition (not shown). The decrease in CTCs seen in the dose-ranging studies may be consistent with this tumoristatic model because of diminished communication between vasculature and tumor deposits.
In summary, cabozantinib is a promising investigational therapy for metastatic CRPC. Cabozantinib is associated with a high rate of bone scan responses, decreases in measurable soft tissue disease, improvements in pain, and decreases in bone biomarkers and CTCs. The primary molecular targets of cabozantinib include VEGFR and MET, although the precise mechanisms responsible for the activity of cabozantinib in metastatic prostate cancer are undefined. Two ongoing randomized controlled trials, COMET-1 and COMET-2, will evaluate the effects of cabozantinib on OS and pain in treatment-refractory metastatic CRPC.
